Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications patient focused benefit risk assessment�� why when how should epidemiologists get
… on: Wednesday, February 27, 2019 Watch the recording When seeking approval for rare disease products, … meet good practice recommendations for health technology assessment submissions. Join us for this webinar where our … webinar where you’ll learn: Health Technology Assessment: How do HTA bodies define rare or ultra-orphan diseases? How …
… settings increases, it is critical to understand how to incorporate real-world evidence (RWE) at every stage … program—from market access, outcomes research, patient preference, and economic evaluation, to reimbursement …
… Equity, Diversity, Inclusion, and Belonging in Patient Centered Drug Development Chad Downey, BS Associate … Advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference … the role patient-preference research can play in patient-focused drug development. The growing recognition of the …
… that ISPE will address in the next few years. At a time when real-world data is gaining visibility among … comparative effectiveness review, and therapeutic risk management. Pharmacoepidemiology is the science that … drug effects. Related Services Pharmacoepidemiology and Risk Management Staff Members Andrea Margulis …
… Solutions experts will be presented at DIA 2024. Effective patient engagement in patient experience data: practical insights from case studies … AM to 9:00 AM Room 6C Session will focus on considerations when using real-world data for post-marketing safety studies, …
… Disease prevalence and public health impact Event rates Patient characteristics Treatment patterns and drug … that available from a single database and experience in patient populations across multiple countries—and if you have …
… Using Primary Data Collection To meet the requirements of risk management programs, inform drug development and … of patients, physicians, and caregivers Evaluate risk management programs including REMS and EU-RMPs Depending …
… physicians, and other stakeholders Advice on utility assessment strategies to support product value, including the identification of appropriate assessment methods, existing health state utility measures, …
… face the common challenge of predicting long-term patient-relevant outcomes from short-term clinical trial … groups’ modeling approaches to understand differences in how they used the clinical trial data in their respective … consider sensitivity analyses that explicitly focus on how treatment effects for new AD treatments are used in …
… to helping reduce risks to patients to ensuring that patient preference is considered in the development of new …